Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by StockNews.com to Buy

StockNews.com lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday morning.

Other equities research analysts have also issued reports about the stock. Bank of America upped their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an underperform rating in a research note on Friday, April 12th. Barclays upped their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a research note on Tuesday, January 23rd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a research note on Wednesday, March 13th. Truist Financial reaffirmed a buy rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada reaffirmed an outperform rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $976.41.

Regeneron Pharmaceuticals Trading Up 0.4 %

REGN opened at $900.16 on Friday. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $98.80 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 2.58 and a beta of 0.11. The company’s 50 day moving average price is $952.07 and its two-hundred day moving average price is $892.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the firm posted $10.96 EPS. The company’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals will post 38.8 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at approximately $17,540,472.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,022 shares of company stock worth $10,552,991. Insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in REGN. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $932,571,000. FMR LLC grew its position in Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares during the period. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares during the period. Global Assets Advisory LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $339,594,000. Finally, First Trust Advisors LP grew its position in Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.